Compare Repligen Corporation Common Stock (RGEN) vs TAL Education Group American Depositary Shares (TAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs TAL Education Group American Depositary Shares — how do they compare? Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B), while TAL Education Group American Depositary Shares trades at $12.44 (market cap $7.01B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and TAL Education Group American Depositary Shares is more actively traded (3,223,678 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and TAL Education Group American Depositary Shares for 3 Days on average.
| RGEN | TAL | |
|---|---|---|
Market Cap | $11.14B | $7.01B |
Volume | 1,259,263 | 3,223,678 |
Sector | Health | Consumer Staples |
52-Week High | $194.57 | $12.91 |
52-Week Low | $102.87 | $8.95 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $11.02B | $4.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TAL Education Group trades at $12.64, down 0.63% with strong bullish technical signals from moving averages. The company demonstrates impressive fundamental strength with 28.43% net income margin and 23.72% ROE, supported by three consecutive earnings beats. Revenue growth accelerated from $2.25B in 2025 to $3.2B in 2026, while profitability surged from $85M to $907M net income. Analyst consensus shows 42.86% buy ratings with price targets suggesting 27.63% upside potential.
TAL presents a compelling investment case with strong earnings momentum and attractive valuation at 7.92 P/E. However, investors face risks from China's regulatory environment and the company's negative cash flow position of -$465.75M in 2025. The technical setup supports near-term upside with key resistance at $13 and support at $12, while institutional sentiment remains positive despite cash flow concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About TAL Education Group American Depositary Shares
TAL Education Group provides smart learning solutions in China. Its offerings combine teaching content, technology, and learning services through various online and offline formats.
Read more on TAL →
